Arcutis Biotherapeutics awarded 269,000 restricted stock units and 70,000 stock options to 40 new employees as inducements under Nasdaq Listing Rule 5635(c)(4). The stock units vest over four years with annual 25% increments, while options vest over four years with a one-year cliff and monthly vesting thereafter. The options have a 10-year term and an exercise price of $23.35, matching the stock's closing price on May 1, 2026. This move aims to attract and retain talent as Arcutis continues developing innovative dermatology treatments.
Venture capitalist Chamath Palihapitiya predicts Taiwan will lose its critical strategic role in semiconductor supply within 18 months as the US rapidly expands its domestic chip manufacturing capabilities. He highlighted that US fabs are nearing the...
The U.S. SEC has acknowledged updated filings for BNB ETFs by VanEck and Grayscale, signaling potential progress toward new U.S.-listed crypto products beyond Bitcoin and Ethereum. Institutional investment shifts include Mubadala increasing its stake...
Asteroid (ASTEROID), a memecoin, experienced a sharp price surge of about 26% following a major whale's purchase of $1.39 million worth of tokens. This whale now holds nearly 4.21 billion ASTEROID tokens and has not sold any, causing the price to jum...
Monero reached a new all-time high near $798 in January 2026, reinforcing its position as the leading privacy coin with mandatory privacy features and strong real-world use. Zcash, with a fixed supply of 21 million and advanced zk-SNARK cryptography,...
In the first quarter of 2026, Intesa Sanpaolo increased its crypto exposure from about $100 million to $235 million, mainly by expanding its Bitcoin ETF holdings. The bank added new positions in Ether via BlackRock’s iShares Staked Ethereum Trust and...
